Core Viewpoint - Jinfang Pharmaceutical-B (02595) experienced significant stock volatility, initially dropping over 8% before recovering to a gain of 6.71%, closing at 28.3 HKD with a trading volume of 44.5183 million HKD [1] Group 1: Clinical Development - Jinfang Pharmaceutical announced the initiation of an Ib/II phase study for its oral high-potency and high-selectivity small molecule KRAS G12D inhibitor GFH375, in combination therapy for treating KRAS G12D mutant advanced solid tumors, with the first patient enrolled at Peking University Cancer Hospital [1] - The study received clinical trial approval from the National Medical Products Administration in September 2023, involving combination therapies with cetuximab or chemotherapy, with GFH375 being part of the first-line treatment regimen for pancreatic ductal adenocarcinoma (PDAC) [1] Group 2: Research Presentation - Data on GFH375 as a monotherapy for KRAS G12D mutant PDAC patients was presented at the 2025 ESMO annual meeting, highlighting its efficacy and safety [1] - The oral presentation was conducted by Professor Zhou Aiping from the Chinese Academy of Medical Sciences Cancer Hospital, focusing on the study data from the 600 mg QD (RP2D) dose group of PDAC patients, demonstrating significant efficacy and manageable safety [1]

Core Viewpoint - The stock of Jinfang Pharmaceutical-B (02595) experienced significant volatility, initially dropping over 8% before recovering to a gain of 6.71%, trading at 28.3 HKD with a transaction volume of 44.52 million HKD. This fluctuation is linked to the announcement of a clinical trial for their KRAS G12D inhibitor GFH375, which has garnered attention due to its potential in treating advanced solid tumors [1]. Group 1 - Jinfang Pharmaceutical announced the initiation of an Ib/II phase clinical trial for GFH375, a small molecule KRAS G12D inhibitor, in combination therapies for KRAS G12D mutant advanced solid tumors [1]. - The trial received approval from the National Medical Products Administration in September 2023 and involves combination therapies with cetuximab or chemotherapy, with GFH375 being part of the first-line treatment for pancreatic ductal adenocarcinoma (PDAC) [1]. - Data from GFH375's monotherapy for KRAS G12D mutant PDAC patients was presented at the 2025 ESMO annual meeting, highlighting its efficacy and safety [1]. Group 2 - The oral presentation at the ESMO meeting was conducted by Professor Zhou Aiping from the Chinese Academy of Medical Sciences, focusing on the efficacy and safety of GFH375 in a specific dosage group of PDAC patients [1]. - The study emphasized the promising results of GFH375 treatment, showcasing its potential as a significant therapeutic option for patients with advanced KRAS G12D mutant PDAC [1].